Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

阿司匹林/阿替洛尔/氢氯噻嗪/雷米普利/辛伐他汀

Report date: 2023/04/25 11:29:41

Base Information

Drug NameAspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin
Drug Alias Name阿替洛尔+雷米普利+氢氯噻嗪+辛伐他汀+阿司匹林Simvastatin/ramipril/atenolol/hydrochlorothiazide/acetylsalicylic acidsimvastatin, ramipril, atenolol, hydrochlorothiazide and acetylsalicylic acidPolycap
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenases inhibitorsAngiotensin-converting enzyme inhibitorsThiazide-sensitive sodium-chloride cotransporter inhibitors +[4] 
TargetsThiazide-sensitive sodium-chloride cotransporterVoltage-gated calcium channelAdrenergic receptors +[6] 
Therapy Area/IndicationsMedication AdherenceHypertensionAtherosclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGhana
CombinationsYes HydrochlorothiazideAtenololRamipril
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCadila Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZydus Lifesciences LtdNorthern California Institute For Research And Education
Inactive CompaniesN/A
Active IndicationsMedication AdherenceHypertensionAtherosclerosis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeC03AX01
Related LinksN/A